Vista Pharma.

Which are the latest news on Vista Pharma.?

Why is Vista Pharmaceuticals Ltd falling/rising?

As of 05-Sep, Vista Pharmaceuticals Ltd's stock price is rising to 6.28, reflecting a short-term gain despite a significant year-to-date decline of 22.85%. The recent increase may not be sustainable due to falling investor participation and mixed signals from moving averages.

As of 05-Sep, Vista Pharmaceuticals Ltd's stock price is rising, currently at 6.28, with a change of 0.04 (0.64%) upwards. This increase can be attributed to the stock outperforming its sector by 1.09% today and experiencing a consecutive gain over the last three days, resulting in a total return of 4.67% during this period. <BR><BR>Despite the positive movement in the short term, it is important to note that the stock has faced significant declines over longer periods, with a year-to-date decrease of 22.85% and a one-year decline of 35.06%. Additionally, the stock's performance relative to the benchmark Sensex shows that while it has outperformed the sector recently, it has underperformed significantly over the longer term. <BR><BR>Investor participation appears to be falling, as indicated by a delivery volume of 2.22 k on September 3, which is down by 73.98% compared to the five-day average. This decline in participation could indicate a lack of confidence among investors, despite the recent price increase. The stock's current price is higher than its five-day moving average but lower than its 20-day, 50-day, 100-day, and 200-day moving averages, suggesting mixed signals regarding its overall trend. <BR><BR>In summary, while Vista Pharmaceuticals Ltd is experiencing a short-term rise in stock price, the broader context of its performance and declining investor participation raises questions about the sustainability of this upward movement.

Who are in the management team of Vista Pharma.?

The management team of Vista Pharma includes Chairman Dhananjaya Alli, Managing Director Murali Meraga, Whole Time Director Pavan Sathvik Gilaka, and Directors Umakanth Katta and Divakar Reddy Yerrabommanahalli, along with several non-executive directors. They collectively guide the company's strategic direction and operations.

The management team of Vista Pharma includes the following individuals:<BR><BR>1. Dhananjaya Alli - Chairman & Wholetime Director<BR>2. Murali Meraga - Managing Director<BR>3. Pavan Sathvik Gilaka - Whole Time Director (Operations)<BR>4. Umakanth Katta - Director<BR>5. Divakar Reddy Yerrabommanahalli - Director<BR><BR>Additionally, the board consists of several non-executive directors:<BR>- G Narendra - Non-Executive & Independent Director<BR>- M H Rao - Non-Executive & Non-Independent Director<BR>- Stanley Prabhakar Reddy - Non-Executive & Non-Independent Director<BR>- Umesh V Banakar - Non-Executive & Independent Director<BR>- Chakravarthula Divya Bhavani - Non-Executive & Independent Director<BR><BR>This team plays a crucial role in guiding the company's strategic direction and operations.

What does Vista Pharma. do?

Vista Pharmaceuticals Ltd formulates pharmaceutical products in the micro-cap market, with a recent net profit of -1 Cr and a market cap of INR 39 Cr. The company was incorporated in 1991 and operates primarily in the pharmaceuticals and biotechnology industry.

Overview: <BR>Vista Pharmaceuticals Ltd is engaged in the formulation of pharmaceutical products, primarily within the pharmaceuticals and biotechnology industry, and operates in the micro-cap market.<BR><BR>History: <BR>Vista Pharmaceuticals Limited was incorporated on January 25, 1991, and obtained its Certificate of Commencement of Business on February 7, 1991. The latest quarterly results reported are for June 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: -1 Cr (Quarterly Results - Jun 2026) <BR>Market-cap value: INR 39 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.27 <BR>Return on Equity: -32.27% <BR>Price-to-Book: 1.07<BR><BR>Contact Details: <BR>Address: Plot No 10to14 16to20 APIIC, Industrial Estate Chotyal Nalgonda Telangana <BR>Phone: 91-09291015956 <BR>Email: admin.hyd@vistapharmaceuticals.com <BR>Website: http://www.vistapharmaceuticals.com

Who are the peers of the Vista Pharma.?

Vista Pharma's peers include ANG Lifesciences, Murae Organisor, Roopa Industries, Chandra Bhagat, Sandu Pharma, Lasa Supergeneri, Medi Caps, JFL Life, and Medicamen Organ. ANG Lifesciences has the highest 1-year return at 20.93%, while Vista Pharma's return is -36.98%.

Peers: The peers of Vista Pharma. are ANG Lifesciences, Murae Organisor, Roopa Industries, Chandra Bhagat, Sandu Pharma., Lasa Supergeneri, Medi Caps, JFL Life, and Medicamen Organ.<BR><BR>Quality Snapshot: Below Average management risk is observed at ANG Lifesciences, Murae Organisor, Roopa Industries, Vista Pharma., Chandra Bhagat, Lasa Supergeneri, and Medicamen Organ., while Average management risk is found at Sandu Pharma. and JFL Life. Growth is Excellent at Roopa Industries, Good at Murae Organisor, and Below Average at the rest. Capital Structure is Good at Sandu Pharma. and Medi Caps, Average at Lasa Supergeneri, and Below Average at all others.<BR><BR>Return Snapshot: The peer with the highest 1-year return is ANG Lifesciences at 20.93%, while the lowest is Murae Organisor at -72.86%. Vista Pharma.'s 1-year return is -36.98%, which is higher than Murae Organisor's but lower than ANG Lifesciences. Additionally, Murae Organisor, Roopa Industries, Sandu Pharma., Lasa Supergeneri, and Medicamen Organ. have negative six-month returns.

How big is Vista Pharma.?

As of 31st August, Vista Pharmaceuticals Ltd has a market capitalization of 39.00 Cr and reported Net Sales of 3.88 Cr with a Net Profit loss of 11.76 Cr over the latest four quarters. Shareholder's Funds are 45.42 Cr and Total Assets are 55.92 Cr as of March 2025.

As of 31st August, Vista Pharmaceuticals Ltd has a market capitalization of 39.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Vista Pharmaceuticals reported Net Sales of 3.88 Cr. However, the company experienced a loss of 11.76 Cr in Net Profit during the same period.<BR><BR>The latest annual reporting period for the balance sheet is March 2025. Shareholder's Funds are recorded at 45.42 Cr, while Total Assets amount to 55.92 Cr.

Should I buy, sell or hold Vista Pharmaceuticals Ltd?

Are Vista Pharmaceuticals Ltd latest results good or bad?

Vista Pharmaceuticals Ltd's latest results are concerning, with net sales dropping to ₹0.00 crore and a net loss of ₹5.86 crores, marking a 290.67% increase in losses year-over-year. The company is facing a severe operational crisis, indicating a bleak outlook for investors.

The latest results for Vista Pharmaceuticals Ltd are quite concerning. In Q4 FY26, the company reported net sales of ₹0.00 crore, marking a staggering 100% decline year-over-year. This represents a complete cessation of revenue generation, which is unprecedented for a company in the pharmaceutical sector. <BR><BR>Additionally, Vista Pharmaceuticals incurred a net loss of ₹5.86 crores in the same quarter, which is a dramatic increase of 290.67% compared to the previous year. The operating margin was effectively 0.0%, indicating that the company is not generating any profit from its operations. The return on equity (ROE) stands at a deeply negative -17.25%, highlighting significant value destruction for shareholders.<BR><BR>Overall, the financial performance indicates a severe operational crisis, with the absence of revenue and escalating losses suggesting that the company is in a critical state. Investors should be cautious, as the outlook appears bleak unless there are immediate and effective measures taken to resume operations.

When is the next results date for Vista Pharmaceuticals Ltd?

The next results date for Vista Pharmaceuticals Ltd is 29 May 2026.

The next results date for Vista Pharmaceuticals Ltd is scheduled for 29 May 2026.

How has been the historical performance of Vista Pharma.?

Vista Pharma has experienced declining financial performance, with net sales dropping from 31.07 Cr in March 2019 to 10.07 Cr in March 2025, and consistent losses reflected in negative operating profits and increasing total liabilities. The company has struggled with cash flow from operations, indicating ongoing financial challenges.

Answer:<BR>The historical performance of Vista Pharma shows a fluctuating trend in net sales and profitability over the years, with significant losses in recent periods.<BR><BR>Breakdown:<BR>Vista Pharma's net sales peaked at 31.07 Cr in March 2019 but have since declined sharply, reaching only 10.07 Cr in March 2025. The total operating income followed a similar pattern, dropping from 22.76 Cr in March 2020 to 10.07 Cr in March 2025. The company has consistently reported negative operating profits, with the operating profit margin excluding other income deteriorating from 3.96% in March 2019 to -40.02% in March 2025. Profit before tax has also remained negative, with a loss of -5.29 Cr in March 2025 compared to a profit of 1.15 Cr in March 2019. The profit after tax reflects this trend, showing a loss of -4.65 Cr in March 2025, down from a profit of 0.94 Cr in March 2019. The company's total liabilities have increased from 50.74 Cr in March 2020 to 55.92 Cr in March 2025, while total assets have also risen from 50.74 Cr to 55.92 Cr in the same period. Cash flow from operating activities has remained negative, indicating ongoing challenges in generating cash from core operations. Overall, Vista Pharma's financial performance has shown a decline in revenue and profitability, with increasing losses over the years.

Is Vista Pharma. overvalued or undervalued?

As of April 25, 2023, Vista Pharma is considered risky and overvalued, with a PE ratio of -9.58 and an EV to EBITDA of -13.00%, significantly underperforming its peers and the Sensex.

As of 25 April 2023, Vista Pharma's valuation grade has moved from does not qualify to risky, indicating a significant shift in its perceived investment quality. The company is currently assessed as overvalued, with a PE ratio of -9.58, an EV to EBITDA of -13.00, and a ROCE of -15.40%. These ratios suggest that the company is struggling financially compared to its peers.<BR><BR>In comparison to its industry peers, Vista Pharma's valuation stands out unfavorably. For instance, Sun Pharma has a PE ratio of 35.25, while Cipla is valued attractively with a PE of 22.99. The stark contrast in these ratios highlights Vista Pharma's challenges in generating positive earnings and returns. Additionally, the company's stock has underperformed against the Sensex over the past year, with a decline of 19.86% compared to the Sensex's gain of 7.60%, further reinforcing the notion that Vista Pharma is currently overvalued.

What is the technical trend for Vista Pharma.?

As of June 5, 2025, Vista Pharma's trend is mildly bearish due to daily moving averages and weekly RSI indicating bearish sentiment, despite some mixed signals from weekly MACD and Bollinger Bands.

As of 5 June 2025, the technical trend for Vista Pharma has changed from bearish to mildly bearish. The current stance is mildly bearish, primarily driven by the daily moving averages indicating a bearish sentiment and the weekly RSI showing bearish momentum. While the weekly MACD and KST are mildly bullish, the monthly indicators remain bearish, suggesting a lack of strong upward momentum. The Bollinger Bands on a weekly basis are bullish, but the overall monthly outlook is mildly bearish. The Dow Theory indicates a mildly bullish trend on the weekly chart, but with no clear trend on the monthly. Overall, the mixed signals across different time frames reflect a cautious outlook for Vista Pharma.

Who are the top shareholders of the Vista Pharma.?

The top shareholders of Vista Pharma include Murali Meraga with 14.62%, Vista Pharmaceuticals Inc. with 10.69%, and individual investors holding 33.62%. There are no foreign institutional investors or pledged promoter holdings.

The top shareholders of Vista Pharma include Vista Pharmaceuticals Inc., which holds 10.69%, and Murali Meraga, who is the highest public shareholder with 14.62%. Additionally, individual investors collectively hold 33.62% of the shares. There are also four mutual fund schemes with a minor holding of 0.02%, but no foreign institutional investors are involved. Notably, there are no pledged promoter holdings in the company.

Has Vista Pharma. declared dividend?

No Dividend History Available